Donepezil (aricept™): The caregivers voice and clinical impression

American Journal of Alzheimer's Disease and other Dementias

Volumn 12, Issue 6, 1997, Pages 272-279

  Shua Haim, Joshua R ^a   Comsti, Eric ^a   Shua Haim, Vered ^b   Ross, Joel S ^a  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b Alzheimer's Research Corporation ARC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0011461523     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/153331759701200605     Document Type: Article

References (29)

1. McKhann G, Drachman D, Folstein M,et al:Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984; 34: 939-944.
2. Folstein MF, Folstein S, Mchugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975; 12: 189-198.
3. Katz S: Assessing self maintenance; Activity of daily living, mobility, and instrumental activity of daily living. J Am Geriatr Soc. 1983; 31: 721-727.
4. Lawton MP: Scale to measure competence in everyday activities. Psychopharm Bull. 1988; 24(4): 609-613.
5. Doraiswamy M: Current Cholinergic Therapy for Symptoms of Alzheimer's disease. J of Primary Psychiatry. November 1996: 1-11.
6. Rabins P, Blacker D, Cohen E: Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. May 1997, Volume 154, Number 5.
7. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Grason SL, Drachman DA, Schneider LS, Whitehouse PJ, Hoover TM, Morris JC, Kawas CH, Knopman DS, Earl NL, Kumar V, Doody RS: Tacrine Collaborative Study Group: A double-blind, placebo-controlled multicenter study of Tacrine for Alzheimer's disease. N Engl J Med. 1992; 327: 1253-1259.
8. Farlow M, Gracon SL, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J: A controlled trial of Tacrine in Alzheimer's disease. JAMA. 1992; 268: 2523-2529.
9. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Grason SL: A 30-week randomized controlled trial of high dose Tacrine in patients with Alzheimer's disease. JAAL 1994; 271: 985-991.
10. Forette F, Hoover T, Gracon S, de Rotrou J, Hervy MP: A double-blind, placebo-controlled, enriched population study of Tacrine in patients with Alzheimer's disease. Eur J Neurology. 1995; 2: 1-10.
11. Foster NL, Petersen RC, Gracon SL, Lewis K: Tacrine 970-6 Study Group: An enriched-population, double-blind, placebo controlled, crossover study of Tacrine and lecithin in Alzheimer's disease. Dementia. 1996; 7: 260-266.
12. Lyketsos CG, Corazzini K, Steele CD, Kraus MF: Guidelines for the use of Tacrine in Alzheimer's disease: Clinical application and effectiveness. J Neuropsychiatry Clin Neurosci. 1996; 8: 67-73.
13. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SL, Lewis KW: Hepatotoxic effects of Tacrine administration in patients with Alzheimer's disease. JAMA. 1994; 271: 992-998.
14. Maning FC: Tacrine therapy for the dementia of Alzheimer's disease. American Family Physician. 1994; 50: 819-823.
15. Rogers SL, Doody R, Mohs R, Friedhoff LT: E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease: Results of a 30-week phase III trial (abstract). Neurology. 1996; 46: 217-217.
16. Rogers SL, Friedhoff LT, Apter JT, Richter RW, Hartford JT, Walse TM, Baumel B, Linden RD, Kinney FC, Doody RS, Borison RL, Ahem GL: The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996; 7: 293-303.
17. Rogers SL, Friedhoff LT: Donepezil (E2020) produces long-term clinical improvement in Alzheimer's disease. Presented at the 4th International Nice/Springfield Symposium on Advances in Alzheimer's Therapy, April 10-14, 1996.
18. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141: 1356-1364.
19. Spencer MP, Folstein MF: The Mini-Mental State Examination. In: Keller PA, Ritt LG: Innovation in clinical practice. A Source Book. 1985; 4: 305-310.
20. Folstein MF, Anthony JC,et al:Meaning of cognitive impairment in the elderly. J Am Geriat Soc. 1985; 33(4): 228-235.
21. Anthony JC, LeResche L, Niaz U,et al:Limits of "Mini-Mental State" as a screening test for dementia and delirium among hospitalized patients. Psych Med. 1982; 12: 397-408.
22. Aricept (Donepezil Hydrochloride) Package Insert. Eisai Inc. and Pfizer US Pharmaceuticals: June 1997.
23. American Psychiatric Association, Committee on Nomenclature and Statistics: Diagnosis and Statistical Manual of Mental Disorders, ed 3, revised. Washington, DC, American Psych Assoc. 1987, p 121-121.
24. Yesavage JA, Brink TL, Rose TL,et al:Development and validation of geriatric depression rating scale: Preliminary report. 1983: 17:27-27.
25. Shua-Haim JR, Sabo MR, Comsti E, Ross JS: Depression in the elderly: Hospital Medicine. July 1997; 44-58.
26. Shikh JI, Yesavage JA: Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. Clin Gerontology. 1986; 5: 170-170.
27. Katz S, Dowens TD, Cash HR: Progress in development of index of ADL. Int J Heath Services. 1976; 6: 493-508.
28. Katz S: A measure of primary sociobiologic function. J Gerontol. 1970; 10(1): 20-30.
29. Lawton MP, Moss M, Fulcomer M,et al:A research and service oriented Multi-level Assessment Instrument. J Gerontol. 1982; 37: 91-97.